



Europass Curriculum Vitae

Personal information

First name(s) / Surname **Paolo Angelo Cortesi**

Address [REDACTED]

Telephone .

Cell phone [REDACTED]

Fax n.a.

E-mail [REDACTED]

Nationality [REDACTED]

Date of birth [REDACTED]

Gender **Male**

Academic qualification

Dates 02-August-2017 – 02-August-2023 (art. 16, comma 1, Legge 240/10)

Role Qualified as Associated Professor

Sector 06/M1 – SSD MED/42 General and applied hygiene (Public Health), nursing sciences and medical statistics

Teaching activity

A.Y. 2019/2020

- *Course* Medicine and Surgery in English (Code LM-41 of the Masters' Degrees in Medicine and Surgery)
- *University* University of Milan Bicocca, Milan, Italy
- *Role* Adjunct professor
- *teaching* Society and Health I

A.Y. 2018/2019

- *Course* Medicine and Surgery in English (Code LM-41 of the Masters' Degrees in Medicine and Surgery)
- *University* University of Milan Bicocca, Milan, Italy
- *Role* Adjunct professor
- *teaching* Society and Health I

- *Course* MSc in Epidemiology and Biostatistics
- *University* Catholic University of the Sacred Heart Rome, Rome, Italy
- *Role* Adjunct professor
- *teaching* Decision Analytic models in Health Care: Markov model

A.Y. 2017/2018

- *Course* MSc in Health Technology and Service Assessment and Management
- *University* University of Milan Bicocca, Milan, Italy
- *Role* Adjunct professor
- *teaching* Decision theory and decision analytic models.

- *Course* MSc in Epidemiology and Biostatistics
- *University* Catholic University of the Sacred Heart Rome, Rome, Italy
- *Role* Adjunct professor
- *teaching* Decision Analytic models in Health Care: Markov model

- *Course* MSc in Health Technology and Service Assessment and Management
- *University* University of Milan Bicocca, Milan, Italy
- *Role* Academic tutor

- *Course* MSc in Pharmacy and Oncology pharmacy
- *University* University of Milan, Milan, Italy
- *Role* Adjunct professor
- *Teaching* Applied pharmacoeconomics in the management of oncology therapies

A.Y. 2016/2017

- *Course* MSc in Health Technology and Service Assessment and Management
- *University* University of Milan Bicocca, Milan, Italy
- *Role* Adjunct professor
- *teaching* Decision theory and decision analytic models.

- *Course* MSc in Epidemiology and Biostatistics
- *University* Catholic University of the Sacred Heart Rome, Rome, Italy
- *Role* Adjunct professor
- *teaching* Decision Analytic models in Health Care: Markov model

- *Course* MSc in Pharmacy and Oncology pharmacy
- *University* University of Milan, Milan, Italy
- *Role* Adjunct professor
- *Teaching* Applied pharmacoeconomics in the management of oncology therapies

A.Y. 2015/2016

- *Course* MSc in Epidemiology and Biostatistics
- *University* Catholic University of the Sacred Heart Rome, Rome, Italy
- *Role* Adjunct professor
- *teaching* Decision Analytic models in Health Care: Markov model

- *Course* MSc in Pharmacy and Oncology pharmacy
- *University* University of Milan, Milan, Italy
 - *Role* Adjunct professor
- *Teaching* Applied pharmacoconomics in the management of oncology therapies

A.Y. 2014/2015

- *Course* MSc in Epidemiology and Biostatistics
- *University* Catholic University of the Sacred Heart Rome, Rome, Italy
 - *Role* Adjunct professor
- *Teaching* Decision Analytical models in Health Care: Markov model

- *Course* MSc in Pharmacy and Oncology pharmacy
- *University* University of Milan, Milan, Italy
 - *Role* Adjunct professor
- *Teaching* Applied pharmacoconomics in the management of oncology therapies

A.Y. 2013/2014

- *Course* MSc in Pharmacy and Oncology pharmacy
- *University* University of Milan, Milan, Italy
 - *Role* Adjunct professor
- *teaching* Applied pharmacoconomics in the management of oncology therapies

Publications (Articles)

- 2019**
- Cortesi PA, Barca R, Giudicatti G, Mossini S, Ciaccio A, Iannazzo S, Micale M, Cesana G, Mantovani LG. Systematic review: economic evaluations of HCV screening in the direct-acting anti-virals era. *Aliment Pharmacol Ther.* 2019 Mar 6. doi: 10.1111/apt.15201. [Epub ahead of print]
 - GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019 Mar 14. pii: S1474-4422(18)30499-X. doi: 10.1016/S1474-4422(18)30499-X. [Epub ahead of print]
- 2018**
- Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagioli S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. *Liver Int.* 2018 Dec;38(12):2170-2177.
 - GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1995-2051.
 - GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1923-1994.
 - GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1789-1858.
 - GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet.* 2018 Nov 10;392(10159):1736-1788.
 - GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life

expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1684-1735. IF 53.2

- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1859-1922.
- Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M. Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. *Patient Prefer Adherence*. 2018 Oct 16;12:2153-2168.
- Belli LS, Perricone G, Adam R, Cortesi PA, Strazzabosco M, Facchetti R, Karam V, Salizzoni M, Andujar RL, Fondevila C, De Simone P, Morelli C, Fabregat-Prous J, Samuel D, Agarwal K, Gonzales EM, Charco R, Zieniewicz K, De Carlis L, Duvoux C; all the contributing centres (www.eltr.org), the European Liver, Intestine Transplant Association (ELITA). Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. *J Hepatol*. 2018 Jun 22. pii: S0168-8278(18)32163-9. doi: 10.1016/j.jhep.2018.06.010.
- GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet*. 2018 Jun 2;391(10136):2236-2271
- Perricone G, Duvoux C, Berenguer M, Cortesi PA, Vinaixa C, Facchetti R, Mazzarelli C, Rockenschaub SR, Martini S, Morelli C, Monico S, Volpes R, Pageaux GP, Fagioli S, Belli LS; European Liver and Intestine Transplant Association (ELITA). Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. *Liver Int*. 2018 May 11. doi: 10.1111/liv.13878. [Epub ahead of print]
- D'Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, Mantovani LG. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. *Pharmacoeconomics*. 2018 May;36(5):567-589.
- Scalone L, Zucco F, Lavano A, Costantini A, De Rose M, Poli P, Fortini G, Demartini L, De Simone E, Menardo V, Meglio M, Cozzolino P, Cortesi PA, Mantovani LG. Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting. *Health Qual Life Outcomes*. 2018 Apr 19;16(1):68. doi: 10.1186/s12955-018-0887-x.
- Cortesi PA, D'Angiolella LS, Lafranconi A, Micale M, Cesana G, Mantovani LG. Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions. *Pharmacoeconomics*. 2018 Mar;36(3):263-284.
- Cortesi PA, Belli LS, Facchetti R, Mazzarelli C, Perricone G, De Nicola S, Cesana G, Duvoux C, Mantovani LG, Strazzabosco M; European Liver and Intestine Transplant Association (ELITA). The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities. *J Viral Hepat*. 2018 Feb 6. doi: 10.1111/jvh.12877. [Epub ahead of print]
- D'Angiolella LS, Lafranconi A, Cortesi PA, Rota S, Cesana G, Mantovani LG. Costs and effectiveness of influenza vaccination: a systematic review. *Ann Ist Super Sanita*. 2018 Jan-Mar;54(1):49-57

2017

- Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. *Blood Adv*. 2017 Dec 12;1(26):2637-2642.
- Lorenzo Giovanni Mantovani, Gianluca Furneri, Paolo Angelo Cortesi, Maria Pia Amato, Achille Patrizio Caputi, Patrizio Piacentini, Alessandra Solari, Carlo Pozzilli, Giancarlo Comi. Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis] Tecfidera® (dimetil fumarato a rilascio ritardato) nel trattamento della sclerosi multipla recidivante-remittente. *Farmeconomia. Health economics and therapeutic pathways 2017*; 18(Suppl 2): 3-76.
- GBD 2016 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1345-1422
- GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries

and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1260-1344.

- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. 2017 Sep 16;390(10100):1211-1259.
- D'Angiolella LS, Cortesi PA, Pitotti C, Ritrovato D, Mantovani LG, Senni M. Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. *Eur J Heart Fail*. 2017 Nov;19(11):1551-1553.
- Andrea Belisari, Daria Bettoni, Paolo Angelo Cortesi, Lucia Sara D'Angiolella, Lorenzo Giovanni Mantovani, Gerardo Miceli Sopo, Marino Nonis. [Nintedanib for the treatment of idiopathic pulmonary fibrosis in Italy] Nintedanib nella terapia della fibrosi polmonare idiopatica in Italia. *Farmeconomia. Health economics and therapeutic pathways* 2017; 18(Suppl 1): 3-41
- Rota M, Cortesi PA, Steinitz-Trost KN, Reiningger AJ, Gringeri A, Mantovani LG. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. *Blood Coagul Fibrinolysis*. 2017 Dec;28(8):627-637.
- Cortesi PA, D'Angiolella LS, Vellucci R, Allegri M, Casale G, Favaretti C, Kheiraoui F, Cesana G, Mantovani LG. Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. *PLoS One*. 2017 Jun 27;12(6):e0179523. doi: 10.1371/journal.pone.0179523. eCollection 2017.
- Lucchese M, Borisenko O, Mantovani LG, Cortesi PA, Cesana G, Adam D, Burdukova E, Lukyanov V, Di Lorenzo N. Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. *Obes Facts*. 2017;10(3):261-272.
- Cortesi PA, Assietti R, Cuzzocrea F, Prestamburgo D, Pluderi M, Cozzolino P, Tito P, Vanelli R, Ceconi D, Borsa S, Cesana G, Mantovani LG. Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery: Analysis From an Italian Administrative Database. *Spine (Phila Pa 1976)*. 2017 Sep 15;42(18):1398-1404.
- Ciaccio A, Cortesi PA, Bellelli G, Rota M, Conti S, Okolicsanyi S, Rota M, Cesana G, Mantovani LG, Annoni G, Strazzabosco M. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. *Liver Int*. 2017 Jul;37(7):982-994.
- Iannazzo S, Cortesi PA, Crea R, Steinitz K, Mantovani LG, Gringeri A. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. *Blood Coagul Fibrinolysis*. 2017 Sep;28(6):425-430.
- D'Angiolella LS, Molinari AC, Cortesi PA, Coppola A, Mantovani LG. Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials. *Farmeconomia. Health economics and therapeutic pathways* 2017; 18(1): 1-4

2016

- Furneri G, Santoni L, Marchesi C, Iannazzo S, Cortesi PA, Caputi AP, Mantovani LG. [Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]. *Farmeconomia. Health economics and therapeutic pathways* 2016; 17(2): 67-80.
- Gualtierotti R, Ingegnoli F, Scalone L, Cortesi P, Bruschi E, Gerosa M, Meroni PL. Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. *Swiss Med Wkly*. 2016;146:w14394
- Belli LS, Berenguer M, Cortesi PA, Strazzabosco M, Rockenschaub SR, Martini S, Morelli C, Donato F, Volpes R, Pageaux GP, Coilly A, Faggioli S, Amaddeo G, Perricone G, Vinaixa C, Bertakovich G, Facchetti R, Polak W, Muiesan P, Duvoux C; European Liver and Intestine Association (ELITA). Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. *J Hepatol*. 2016 Sep;65(3):524-31.
- Vellucci R, Fanelli G, Cortesi PA, Pannuti R, Peruselli C, Romualdi P; Working Group Nientemale DEI. Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. *Drugs*. 2016 Jul;76(10):1063-5.
- Mantovani LG, Cortesi PA, Strazzabosco M. Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. *Hepatology*. 2016 Oct;64(4):1331-42.
- Scalone L, Cortesi PA. About the Reliability of the Critical Review to Investigate the Generalizability of Economic Evaluations Conducted in Italy. *Value Health*. 2016 Jul-Aug;19(5):697.
- Rocino A, Cortesi PA, Scalone L, Mantovani LG, Crea R, Gringeri A; European Haemophilia Therapy Strategy Board (EHTSB). Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). *Haemophilia*

2016 Jan;22(1):96-102.

- Olivieri I, Cortesi PA, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, Cantini F, Ciampichini R, Cutro MS, Mathieu A, Matucci-Cerinic M, Punzi L, Scarpa R, Mantovani LG; PACE Working Group. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. *Clin Exp Rheumatol*. 2016 Jan-Feb;34(1):68-75

2015

- Cortesi PA, Mantovani LG, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M, Belli LS. Cost-effectiveness of new direct acting antivirals to prevent post-liver transplant recurrent hepatitis. *Am J Transplant*. 2015 Jul;15(7):1817-26.
- Valente M, Cortesi PA, Lassandro G, Mathew P, Pocoski J, Molinari AC, Mantovani LG, Giordano P. Health economic models in Hemophilia A and Utility Assumptions from a Clinician's Perspective. *Pediatr Blood Cancer*. 2015 Oct;62(10):1826-31.
- Cortesi PA, Kheiraoui F, Casale G, Favaretti C, Guarrera G, Aprile PL, Piacentini P, Mantovani LG. Budget impact analysis del fentanyl citrato sublinguale nella gestione del breakthrough Cancer Pain. *QJPH*. 2015, 4(3):1-14.
- Scalone L, Cortesi PA. Cost-utility analysis of biologic therapies to treat chronic plaque psoriasis in Italy: the importance of using updated and adequate social tariffs to calculate quality-adjusted life-years. *BioDrugs*. 2015 Feb;29(1):69.
- Cortesi PA, Scalone L, Mantovani LG. Cost-Effectiveness Analysis of New Drugs for Chronic Hepatitis C: The Importance of Updating Utility Values. *Hepatology*. 2015 Mar;61(3):1096-7.
- Scalone L, Cortesi PA, Ciampichini R, Cesana G, Mantovani LG. Health related quality of life norm data of the general population in Italy: Results using the EQ-5D-3L and EQ-5D-5L instruments. *Epidemiology Biostatistics and Public Health* 12(3),e11457.
- Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. *J Viral Hepat*. 2015 Feb;22(2):175-83.
- Scalone L, Cortesi PA, Mantovani LG, Belisari A, Ayala F, Fortina AB, Bonamonte D, Borroni G, Cannavò SP, Guarneri F, Cristaudo A, De Pità O, Gallo R, Girolomoni G, Gola M, Lisi P, Pigatto PD, Satta R, Giannetti A; The Italian Hand Eczema Study Group. Clinical epidemiology of hand eczema in patients accessing dermatological reference centers: results from a Mediterranean Country. *Br J Dermatol*. 2015 Jan;172(1):187-95.

2014

- Cortesi PA, Scalone L, Giannetti A, Angelini G, Belisari A, Cannavò SP, Cristaudo A, De Pità O, Gallo R, Gola M, Pigatto P, Mantovani LG, IHESG. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. *Contact Dermatitis*. 2014 Mar;70(3):158-68.

2013

- Scalone L, Cortesi PA, Ciampichini R, Belisari A, D'Angiolella LS, Cesana G, Mantovani LG. Italian population-based values of EQ-5D health states. *Value Health*. 2013 Jul-Aug;16(5):814-22.
- di Pietro ML, Kheiraoui F, de Waure C, Specchia ML, Cadeddu C, Capizzi S, Gualano MR, Sferrazza A, Nicolotti N, Ferriero AM, Veneziano MA, di Nardo F, Gliubizzi MD, La Torre G, Saulle R, Zollo A, Reggio P, Mantovani L, Furneri G, Cortesi P. Il vaccino pneumococcico 13-valente per la prevenzione delle infezioni da *S. pneumoniae* in età adulta: una valutazione di HTA. *QJPH* 2013 - Vol: 2 - Num. 4.
- Scalone L, Cortesi PA, Spinella G, Pane B, Cesana G, Mantovani LG, Palombo D. Use of health-related quality-of-life measurements to value individuals' health on screening: the experience of the SAGE program. *Acta Chir Belg*. 2013 Nov-Dec;113(6):406-14.
- Gringeri A, Leissing C, Cortesi PA, Jo H, Fusco F, Riva S, Antmen B, Berntorp E, Biasoli C, Carpenter S, Kavakli K, Morfini M, Négrier C, Rocino A, Schramm W, Windyga J, Zülfiqar B, Mantovani LG. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. *Haemophilia*. 2013 Sep;19(5):736-43.

- Cortesi PA, Mencacci C, Luigi F, Pirfo E, Berto P, Sturkenboom MC, Lopes FL, Giustra MG, Mantovani LG, Scalone L. Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. *BMC Psychiatry*. 2013 Mar 22;13:98.

2012

- Palla I, Trieste L, Tani C, Talarico R, Cortesi PA, Mosca M, Turchetti G. *Clin Exp Rheumatol. A Systematic Literature Review Of The Economic Impact Of Ankylosing Spondylitis*. 2012 Jul-Aug;30(4 Suppl 73):S136-41.
- Turchetti G, Scalone L, Della Casa Alberighi O, Mosca M, Montella S, Cortesi PA, Mantovani LG. *The Rationale Of Pharmacoeconomic Analysis In Rheumatologic Indications*. *Clin Exp Rheumatol*. 2012 Jul-Aug;30(4 Suppl 73):S64-71.
- Furneri G, Mantovani LG, Belisari A, Mosca M, Cristiani M, Bellelli S, Cortesi PA, Turchetti G. *Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis*. *Clin Exp Rheumatol*. 2012 Jul-Aug;30(4 Suppl 73):S72-84.
- Luciana Scalone; Mario Carminati; Philipp Bonhoeffer; Paolo A Cortesi; Lorenzo G Mantovani; Giancarlo Cesana; John Hess. *Patients' and physicians' needs, experiences and preferences in the treatment of right ventricular outflow tract dysfunction*. *IJPH - 2012, Volume 9, Number 2*

2011

- Leissingner C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zulfikar B, Mantovani L. *Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors*. *N Engl J Med*. 2011 Nov 3;365(18):1684-92.
- Simona de Portu, Sabato Montella, Paolo Cortesi, Enrica Menditto, Lorenzo G. Mantovani. *Valutazione economica dello studio CARDS: un aggiornamento. Farmeconomia e percorsi terapeutici*. 2011; 12(Suppl 2): 41-52.
- Simona de Portu, Sabato Montella, Paolo Cortesi, Enrica Menditto, Lorenzo G. Mantovani. *Valutazione economica dello studio CARDS: un aggiornamento. Farmeconomia e percorsi terapeutici*. 2011; 12(Suppl 2): 35-40.

2010

- Gualtierotti R, Scalone L, Ingegnoli F, Cortesi P, Lubatti C, Zeni S, Meroni PL. *Health related quality of life assessment in patients with systemic sclerosis*. *Reumatismo*. 2010 Jul-Sep; Vol. 62(3): 210-214.
- Lorenzo G. Mantovani, Simona de Portu, Paolo A. Cortesi, Andrea Belisari. *Valutazione economica del vaccino coniugato 13-valente*. *IJPH - Year 8, Volume 7, Number 2, Suppl. 1, 2010; S38-S47*.

**Publications
(Books)**

2017

- *Health Technology Assessment e Sanità Pubblica - Journal of Preventive Medicine and Hygiene Suppl. 1. Vol 58, No 3 (2017)*.
Chapter: Gasparini R, Boccacini S, Cortesi PA, Mantovani LG, De Waure C. *The methodology. Health evaluation. Domains, methods, and criteria [La metodologia. La valutazione in Sanità. Domini, metodi e criteri]* Pages E20-E25.

2011

- Mantovani L. *Health Technology Assessment*. Publishing house: Il Sole 24 ORE. 2011. (Cortesi PA role: drafting the book examples)

**Scientific congress
activity**

Dates	6 February – 8 February 2019
Society	European Association for Haemophilia and Allied Disorders
Congress	12th Annual Congress
Role	Invited speaker (SESSION 1: Gene therapy in haemophilia - How (much) can we pay for gene therapy in haemophilia?)

Dates 29 October - 2 November 2016
 Society International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
 Congress ISPOR 19th Annual European Congress, Vienna
 Role Research Review Committee Co-Chair

Dates 7-11 November 2015
 Society International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
 Congress ISPOR 18th Annual European Congress, Milan
 Role Research Review Committee Co-Chair

Dates 20-21 June 2013
 Society Italian Association for the Study of the Liver (AISF)
 Congress 9th AISF Single Topic Conference, Milan
 Role Member of the Scientific Committee

Scientific societies or international research group

Member of the Global Burden of Diseases (GBD) project. A project that quantify health loss from hundreds of diseases, injuries, and risk factors, so that health systems can be improved and disparities can be eliminated, since 2017

Member of the European Liver and Intestine Transplant Association (ELITA) studies to assess the clinical, epidemiological and economic impact of HCV and HBV therapies on the liver transplants in Europe, since 2016

Member of the Health Technology Assessment (HTA) working group – SITI, since 2016

Member of the Health Technology Assessment (HTA) working group – EUPHA, since 2016

Member of EUPHA - European Public Health Association, since 2015

Member of SITI - Italian Society of Hygiene, Preventive Medicine and Public Health, since 2015

Member of the VBMH (Value based Medicine in Hepatology) study group, involved in a project with the aim to identify clinical and patients reported outcomes to assess the Quality of care in the Liver diseases centers, since 2010

Member of ISPOR—The Professional Society for Health Economics and Outcomes Research, since 2008

Education and training

Dates July, 7th-18th 2014
 Title of qualification awarded Utrecht University summer school
 Principal subjects/occupational skills covered Infectious diseases, Mathematical Modelling
 Name and type of organisation providing education and training University of Utrecht, Utrecht, Netherland.
 Level in national or international classification Summer school

Dates April, 17th-19th 2013
 Title of qualification awarded HEHTA's professional course
 Principal subjects/occupational skills covered Systematic Review and Meta-Analysis of Direct, Indirect and Mixed Treatment Evidence
 Name and type of organisation providing education and training University of Glasgow, Glasgow, Scotland.

Level in national or international classification	Professional course
Dates	September, 12th-14th 2012
Title of qualification awarded	HEHTA's professional course
Principal subjects/occupational skills covered	Decision Analytic Modelling for Economic Evaluation
Name and type of organisation providing education and training	University of Glasgow, Glasgow, Scotland.
Level in national or international classification	Professional course
Dates	July, 9th-13th 2012
Title of qualification awarded	Centre for Health Economics' expert work shop.
Principal subjects/occupational skills covered	Advanced methods for cost-effectiveness analysis: meeting decision-makers' requirements
Name and type of organisation providing education and training	<i>University of York, St. William's College, York, UK.</i>
Level in national or international classification	Professional course
Dates	January 2010 – January 2013
Title of qualification awarded	PhD in Epidemiology and Biostatistics
Principal subjects/occupational skills covered	Epidemiology, Public health, Health technology assessment and Outcome research
Name and type of organisation providing education and training	University of Milan-Bicocca, Faculty of Medicine
Level in national or international classification	PhD Studies, post-graduate training
Dates	October 2005 - July 2008
Title of qualification awarded	Master of Science
Principal subjects/occupational skills covered	Drug Biotechnology
Name and type of organisation providing education and training	University of Milan, Faculty of Pharmacy
Level in national or international classification	Final mark 108/110
Dates	October 2002 - February 2006
Title of qualification awarded	Beachelor of Science
Principal subjects/occupational skills covered	Pharmaceutical Biotechnology
Name and type of organisation providing education and training	University of Milan, Faculty of Pharmacy
Level in national or international classification	Final mark 107/110

Work experience

Dates	January 2017 – up until today
Occupation or position held	Research fellow
Main activities and responsibilities	Planning and coordination of health-economic evaluations, public health and outcomes research studies on different topics. Planning and coordination of health technology assessment of screening program in infection diseases, with particular interest in Chronic HCV. Involvement in the European Liver and Intestine Transplant Association (ELITA) studies to assess the clinical, epidemiological and economic impact of HCV and HBV therapies on the liver transplants in Europe. Member of the VBMH (Value based Medicine in Hepatology) study group, involved in a project with the aim to identify clinical and patients reported outcomes to assess the Quality of care in the Liver diseases centers. Member of the Global Burden of Diseases (GBD) project. A project that quantify health loss from hundreds of diseases, injuries, and risk factors, so that health systems can be improved and disparities can be eliminated. Member of the study group on the role of nurses in the Multiple Sclerosis management. A project of the Network of Multiple Sclerosis Centres in the Lombardy region (Italy).
Name and address of employer	Research Center on Public Health CESP – University of Milan-Bicocca; Villa Serena, Via Pergolesi 33, Monza 20052, Italia
Type of business or sector	Public Health and Health Economics
Dates	June 2013 – December 2016
Occupation or position held	Program lead in decision analytic modeling
Main activities and responsibilities	Planning and building decision analytical models to perform economic-evaluation of health technologies. Reviewing and customizing decision analytic models for Italian market.
Name and address of employer	<i>Charta Foundation; Via Visconti di Modrone 18, Milano, 20122, Italy</i>
Type of business or sector	Decision analytical modelling, Health economics and outcomes research
Dates	February 2013 – October 2013
Occupation or position held	Visiting research fellow
Main activities and responsibilities	Planning and building decision analytical models to assess: the cost-utility of different screening strategies for HCV, HBV and HIV; and the cost-utility of a new diagnostic technology for ischemic stroke.
Name and address of employer	<i>Health Economics & Health Technology Assessment - Institute of Health & Wellbeing, University of Glasgow; 1 Lilybank Gardens, Glasgow G12 8RZ</i>
Type of business or sector	Health economics and Decision analytical modelling
Dates	February 2013 – December 2016
Occupation or position held	Collaborator
Main activities and responsibilities	Planning and coordination of health-economic evaluations and outcomes research on different topics. Management and analysis of datasets. Planning and building decision analytical model to assess health interventions in different field. Member of the VBMH (Value based Medicine in Hepatology) study group, involved in a project with the aim to identify clinical and patients reported outcomes to assess the Quality of care in the Liver diseases centers.
Name and address of employer	Research Center on Public Health CESP – University of Milan-Bicocca; Villa Serena, Via Pergolesi 33, Monza 20052, Italia
Type of business or sector	Public Health and Health Economics
Dates	January 2010 – December 2016
Dates	June 2012 – August 2012
Occupation or position held	Consultant

Main activities and responsibilities	Coordinator of an expert panel of hematologists with the aim to identify all costs associated with the treatment of patients with hemophilia A.
Name and address of employer	<i>University "Scuola Superiore Sant'Anna di Pisa"; Piazza Martiri della Libertà, 33 - 56127 Pisa (Italia)</i>
Type of business or sector	Health Management
Dates	January 2011 – December 2011
Occupation or position held	Consultant
Main activities and responsibilities	Planning and coordination of health-economic evaluations and outcomes research in Hemophilia, Arthritis Psoriatic and Chronic Hand Eczema. Data management and analysis of clinical, health economic and outcomes datasets.
Name and address of employer	<i>Charta Fondation; Via Visconti di Modrone 18, Milano, 20122, Italia</i>
Type of business or sector	Health Economics and outcomes research
Dates	May 2010 – October 2012
Occupation or position held	Consultant
Main activities and responsibilities	Health technology assessments
Name and address of employer	General Health Directorate of Lombardy Region. U.O. Governo dei servizi sanitari territoriali e politiche di appropriatezza e controllo. Valutazione Tecnologie Sanitarie – VTS (Health Technology Assessment - HTA), Via Pola 9/11, Milano, 20124, Italia.
Type of business or sector	Public Health and Health Economics.
Dates	January 2010 – January 2013
Occupation or position held	PhD Student
Main activities and responsibilities	Planning and coordination of health-economic evaluations and outcomes research on different topics. Management and analysis of datasets. Planning and building decision analytical model to assess the cost-utility of the new protease inhibitors for the treatment of Chronic HCV. Member of the VBMH (Value based Medicine in Hepatology) study group, involved in a project with the aim to identify clinical and patients reported outcomes to assess the Quality of care in the Liver diseases centers.
Name and address of employer	Research Center on Public Health CESP – University of Milan-Bicocca; Villa Serena, Via Pergolesi 33, Monza 20052, Italia
Type of business or sector	Public Health and Health Economics
Dates	July 2008 – May 2010
Occupation or position held	Project manager
Main activities and responsibilities	Planning and coordination of health-economic evaluations and outcome research. Data management and analysis of different datasets.
Name and address of employer	<i>Charta Fondation; Via Visconti di Modrone 18, Milano, 20122, Italia</i>
Type of business or sector	Health Economics and outcomes research
Dates	April 2007 – December 2009
Occupation or position held	Postgraduate scholarships
Main activities and responsibilities	Planning and coordination of health-economic evaluations and outcome research. Data management and analysis of different datasets.
Name and address of employer	Centre for Health Technology assessment and Outcomes Research, Department of Medical Pharmacology, University of Milan. Via Vanvitelli 32, 20129-Milan (Italy).
Type of business or sector	Public Health and Health Economics
Dates	June 2005 – July 2005
Occupation or position held	Internship

Main activities and responsibilities	Management and analysis of infectious diseases database to assess the economic impact of infectious disease in hospital setting.
Name and address of employer	Centre of Pharmacoeconomics, University of Milan. Via Balzaretti 9, 20133-Milan (Italy).
Type of business or sector	Pharmacoeconomics
Dates	March 2005 – December 2005
Occupation or position held	Internship
Main activities and responsibilities	Application of the method of reverse transcriptase-Polymerase Chain Reaction to the study of changes in splicing of pre-mRNA for Doublecortin in Neuroblastoma.
Name and address of employer	Institute of Endocrinology – University of Milan; Via Balzaretti 9, Milano, 20129, Italia.
Type of business or sector	Molecular Biology

"In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document."

Date: 11-Sept-2019

In witness whereof,
Paolo Angelo Cortesi

